Estradiol measurement in translational studies of breast cancer
Peer reviewed, Journal article
Published version

Åpne
Permanent lenke
https://hdl.handle.net/1956/11693Utgivelsesdato
2015-07Metadata
Vis full innførselSamlinger
Originalversjon
https://doi.org/10.1016/j.steroids.2014.08.008Sammendrag
Plasma estrogen measurement with use of radioimmunoassays has been instrumental in the development of aromatase inhibitors for endocrine therapy of postmenopausal breast cancer. However, due to low plasma estrogen concentrations in postmenopausal women, direct radioimmunoassays lack the sensitivity required. While certain laboratories have developed highly sensitive assays for research purposes revealing plasma estrogen suppression consistent with results from tracer studies, such assays are time and labor-consuming due to need for pre-analytical chromatographic purification, sample concentration and sometimes conversion of precursors to products. While novel chromatographic methods involving mass spectrometry analysis are likely to replace such radioimmunoassays in the future, so far a limited number of laboratories have developed suitable assays with a detection limit (around 1 pM) that is required for analyzing plasma estrogen levels in patients during treatment with potent aromatase inhibitors.